New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 14, 2012
07:31 EDTACRXAcelRx announces top-line data from Phase 3 study of Sufentanil NanoTab
AcelRx Pharmaceuticals announced top-line data from its previously announced open-label, active-comparator study of its lead product candidate, the Sufentanil NanoTab PCA System. Top-line results of the Phase 3 clinical trial demonstrate that the Sufentanil NanoTab PCA System was non-inferior to intravenous patient-controlled analgesia with morphine for the primary endpoint of Patient Global Assessment of method of pain control over the 48-hour study period as determined by the combined percentage of patients with PGA ratings of "good" or "excellent".
News For ACRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 24, 2014
07:56 EDTACRXAcelRx management to meet with BofA/Merrill
Meeting to be held in New York on October 29 hosted by BofA/Merrill.
October 22, 2014
07:19 EDTACRXAcelRx's Zalviso for abdominal pain shows positive Phase 3 results
Subscribe for More Information
October 16, 2014
07:02 EDTACRXAcelRx updates patent portfolio for Zalviso and platform technologies
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use